Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Jefferies Reinstates Talen Energy (TLN) at Hold